AbbVie Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net revenues of $6,796 million compared to $6,400 million a year ago. Operating earnings were of $2,358 million compared to $2,113 million a year ago. Earnings before income tax expenses were of $1,998 million compared to $1,924 million a year ago. Net earnings were $1,391 million or $0.85 per diluted share compared to $1,517 million or $0.92 per diluted share a year ago. Adjusted diluted earnings per share were $1.20 compared to $1.13 a year ago. Adjusted pre-tax earnings were $2,461 million compared to $2,376 million a year ago. Adjusted after-tax earnings were $1,964 million compared to $1,861 million a year ago.

For the year, the company reported net revenues of $25,638 million compared to $22,859 million a year ago. Operating earnings were of $9,384 million compared to $7,537 million a year ago. Earnings before income tax expenses were of $7,884 million compared to $6,645 million a year ago. Net earnings were $5,953 million or $3.63 per diluted share compared to $5,144 million or $3.13 per diluted share a year ago. Adjusted diluted earnings per share were $4.82 compared to $4.29 a year ago. Adjusted pre-tax earnings were $9,905 million compared to $9,040 million a year ago. Adjusted after-tax earnings were $7,904 million compared to $7,060 million a year ago.

For the first quarter, the company expects adjusted earnings per share between $1.24 and $1.26. First quarter adjusted EPS guidance excludes roughly $0.23 of noncash amortization and other specified items. The company forecasts revenue growth in the first quarter to approach 10% operationally. For U.S. HUMIRA, The company expects sales growth in the first quarter to exceed 20% over the prior year. And expects U.S. IMBRUVICA sales in the first quarter to grow in the high single digits sequentially over the fourth quarter.

The company provided earnings guidance for the full year of 2017. The company expects GAAP diluted EPS for the full-year 2017 of $4.55 to $4.65. The company expects to deliver adjusted diluted EPS guidance for the full-year 2017 of $5.44 to $5.54, representing growth of 13.9% at the mid-point. The company's 2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other specified items. The company forecasts adjusted net interest expense of approximately $1 billion for the full year, and expects an adjusted tax rate of approximately 19.5% to 20% in 2017.